Belvedere Trading
APLT

Belvedere Trading’s Applied Therapeutics APLT Stock Holding History

Belvedere Trading’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,236
Closed -$81.9K – 686
2023
Q4 		$61.1K Buy
+18,236
New +$45.4K ﹤0.01% 541
2023
Q3 		– Sell
-8,602
Closed -$11K – 645
2023
Q2 		$11K Buy
+8,602
New +$11.4K ﹤0.01% 710

Other funds holding APLT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Belvedere Trading's APLT Position: Q1 2024 in Review

Belvedere Trading sold out of Applied Therapeutics (APLT) in Q1 2024, closing a stake of 18,236 shares — an estimated $81.9K sold.

Belvedere Trading first reported a position in APLT in Q2 2023 and held it in 2 quarters. The position peaked at $61.1K in Q4 2023. 89 funds tracked by Wall St. Rank hold APLT as of Q1 2024.

  • Belvedere Trading reported no remaining Applied Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Belvedere Trading sold 18,236 Applied Therapeutics shares in Q1 2024, an estimated $81.9K.
  • Belvedere Trading first reported a position in Applied Therapeutics in Q2 2023 and held it in 2 quarters.
  • Belvedere Trading's Applied Therapeutics position peaked at $61.1K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.